Clear Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, accounting for roughly 70 to 80 percent of all renal cell carcinoma diagnoses. The name comes from how the tumor cells look under a microscope: their cytoplasm appears pale or “clear” because it is packed with lipids and glycogen that dissolve during standard tissue processing. But ccRCC is far more than a pathology curiosity. It is a disease driven by a specific and well-understood genetic event, and that understanding has reshaped how it is diagnosed, treated, and monitored.

Why the Cells Look “Clear”

The hallmark appearance of ccRCC cells comes from an unusual metabolic quirk. These tumor cells stockpile large amounts of lipid droplets and glycogen inside themselves. When tissue is prepared for microscopic examination, standard chemical fixation washes those lipids and glycogen away, leaving behind empty-looking cells with a clear, washed-out appearance. Research into the lipid composition of these tumors has found that the stored fats are roughly half cholesteryl esters and half triacylglycerols, with the cholesteryl esters dominated by cholesteryl oleate. Normal kidney tissue, by contrast, stores far less of these lipids and favors a different type of cholesteryl ester.¹ This abnormal lipid and glycogen hoarding is not just cosmetic. ccRCC is increasingly viewed as fundamentally a metabolic disease, with disrupted energy pathways playing a central role in how the cancer grows and survives.²

The VHL Gene and How ccRCC Gets Started

The overwhelming majority of ccRCC tumors share one key event: loss or silencing of the VHL gene on chromosome 3p. The VHL gene encodes a protein that works as a kind of cleanup crew, tagging certain other proteins for destruction when they are no longer needed. Its most important target in this context is a group of transcription factors called HIF-alpha subunits, which normally accumulate only when oxygen is low. When VHL is working properly, it marks HIF-alpha for degradation under normal oxygen conditions. When VHL is knocked out, HIF-alpha builds up regardless of oxygen levels, and the cell behaves as though it is starving for oxygen even when it is not.

VHL is mutated or silenced in more than half of sporadic (non-inherited) ccRCC cases.³ Loss of chromosome 3p, the region where VHL sits, is dramatically more common in tumors with VHL inactivation than in those without it.⁴ This makes VHL loss something close to a founding event in most ccRCC tumors, the genetic domino that sets the rest in motion.

HIF-2α and the Oxygen-Sensing Pathway Gone Wrong

Once VHL is gone, the cell accumulates two related proteins: HIF-1α and HIF-2α. These two have overlapping but distinct effects. Research has shown that HIF-2α is the more potent driver of ccRCC growth. In animal models, tumors expressing HIF-2α grew significantly faster than controls, while HIF-1α actually slowed tumor growth.⁵ HIF-2α and HIF-1α also interact differently with the cancer-promoting protein c-Myc, with HIF-2α cooperating with it while HIF-1α can actually oppose it.⁶

One of the most consequential things HIF-2α does is switch on genes that promote new blood vessel growth, especially vascular endothelial growth factor (VEGF). This makes ccRCC tumors unusually rich in blood vessels, which is part of what makes them aggressive but also creates a therapeutic vulnerability. Drugs that block VEGF or its receptor have become a cornerstone of treatment, and ccRCC tumors are especially sensitive to VEGF deprivation.⁷

Beyond VHL: The Three Genes on Chromosome 3p

VHL loss alone is not enough to produce a full-blown cancer. Three additional genes on the same stretch of chromosome 3p frequently get deleted alongside VHL, and their loss shapes how the tumor behaves and how a patient is likely to fare. These genes, PBRM1, BAP1, and SETD2, all play roles in how the cell organizes and reads its own DNA.⁸

The clinical implications of these mutations differ sharply. PBRM1 loss, found in about 40 percent of ccRCC cases, tends to be associated with slower-growing tumors and may predict sensitivity to drugs that target blood vessel growth. BAP1 mutations, occurring in roughly 10 to 15 percent of tumors, are a much worse sign: they predict higher-grade tumors, aggressive features, and poorer survival. SETD2 mutations, also present in about 10 to 15 percent of cases, cause genomic instability and are linked to aggressive disease but may also improve the response to immune-based treatments.⁹ In clinical trials comparing targeted drugs, patients with PBRM1 mutations who received the mTOR inhibitor everolimus had a median progression-free survival of about 13 months, compared to roughly 5.5 months for those without the mutation. Meanwhile, BAP1-mutated tumors on the same drug did noticeably worse.¹⁰

Who Gets It and What Raises Risk

The established risk factors for kidney cancer in general, and ccRCC specifically, are smoking, obesity, and high blood pressure.¹¹ Higher cigarette consumption is linked to both increased incidence and increased death from the disease, though researchers still do not fully understand exactly how smoking triggers kidney cancer at a molecular level. Obesity raises risk as well, but there is an odd wrinkle: once a person has been diagnosed, being obese appears to be associated with somewhat better survival outcomes, a phenomenon sometimes called the obesity paradox.¹² Whether this reflects biology, earlier detection in patients receiving more medical attention for weight-related conditions, or some other confounding factor remains unclear.

A small fraction of ccRCC cases are hereditary. The best known inherited form is von Hippel-Lindau disease, caused by a germline mutation in the VHL gene. People with VHL disease are at sharply increased risk for ccRCC as well as hemangioblastomas (blood vessel tumors) in the brain, spinal cord, and eyes.¹³ Genetic counseling and regular surveillance imaging are standard for these patients. Most ccRCC, however, is sporadic, meaning it arises from mutations acquired during a person’s lifetime rather than inherited from a parent.

How ccRCC Is Usually Found

One of the more unsettling facts about kidney cancer is that it often produces no symptoms until it is advanced. The classic triad of flank pain, blood in the urine, and a palpable mass actually shows up in only a minority of cases. Most ccRCC today is discovered by accident. A large UK study found that about 60 percent of renal cell carcinoma cases were diagnosed incidentally, typically during imaging for some completely unrelated complaint like abdominal pain or a routine health check.¹⁴ Among patients with the smallest, most localized tumors, the incidental detection rate climbed to 87 percent. The good news is that incidentally discovered tumors tend to be smaller, lower-grade, and caught at earlier stages, which translates to significantly better cancer-specific survival compared to tumors found because of symptoms.¹⁵

Surgery for Localized Disease

When ccRCC is caught early and confined to the kidney, surgery is the primary treatment. The two main options are partial nephrectomy (removing just the tumor and a margin of normal tissue) and radical nephrectomy (removing the entire kidney). For smaller tumors, partial nephrectomy has gained strong favor because it preserves kidney function while achieving comparable cancer control. A study of older patients with early-stage kidney cancer found that those who had partial nephrectomy had significantly better overall survival, with a predicted survival advantage of roughly 15 percentage points at eight years compared to radical nephrectomy.¹⁶ That benefit appeared to come not from better cancer-specific outcomes but from preserving kidney function and avoiding the long-term consequences of reduced renal capacity.

For somewhat larger tumors, in the 4 to 7 centimeter range, the comparison is less settled. One study found that patients who had partial nephrectomy had significantly lower creatinine levels (a marker of kidney function) three months after surgery, but the cancer recurrence rates were too low in both groups to show a statistically meaningful difference in disease control with the follow-up available.¹⁷ Population-level data has also supported better overall and cancer-specific survival with partial nephrectomy for these intermediate-sized tumors.¹⁸

Ablative Alternatives to Surgery

Not every patient can undergo or wants surgery. For small, localized tumors, several ablative techniques offer alternatives. These include cryoablation (freezing the tumor), radiofrequency ablation (heating it), microwave ablation, and stereotactic body radiotherapy (SBRT), which delivers highly focused radiation. A systematic review and meta-analysis found that local control rates for SBRT were about 99 percent at one year and 95 percent at five years.¹⁹ Head-to-head comparisons between techniques suggest they produce broadly similar outcomes for early-stage disease. One study comparing SBRT with radiofrequency ablation found three-year freedom from local recurrence of about 99 percent versus 92 percent, with no statistically significant difference in disease-free or overall survival between the two.²⁰

Treating Metastatic ccRCC

When ccRCC spreads beyond the kidney, the treatment landscape changes dramatically. Surgery alone is rarely curative for metastatic disease, and chemotherapy has historically been ineffective against kidney cancer. Instead, the field has centered on two classes of systemic therapy: drugs that target blood vessel growth (VEGF pathway inhibitors) and immune checkpoint inhibitors that help the immune system recognize and attack tumor cells.

Current guidelines from major urology and oncology organizations now consider combinations of these two drug classes as the standard first-line approach for metastatic ccRCC. Multiple large trials have shown that pairing an immune checkpoint inhibitor with a VEGF-targeting drug beats older single-agent targeted therapy. Combinations like lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, and axitinib plus pembrolizumab have all demonstrated improvements in progression-free survival, overall survival, or both compared to sunitinib alone. For patients with intermediate or poor prognostic features, the combination of ipilimumab plus nivolumab (two immune checkpoint inhibitors, no VEGF drug) has shown a durable overall survival benefit, with progression-free survival plateauing after about 30 months.²¹

When first-line immunotherapy fails, VEGF-targeting drugs remain effective as second-line treatment. In one study of patients who had already received immune checkpoint inhibitors, roughly 40 percent achieved a partial response on a second-line VEGF receptor inhibitor, and more than half had stable disease, with a median progression-free survival of about 13 months.²²

Belzutifan and the Rise of HIF-2α Inhibitors

Because HIF-2α is so central to how ccRCC works, it has become an attractive drug target. Belzutifan is the first drug in a new class that blocks HIF-2α directly, preventing it from switching on the genes that drive tumor growth and blood vessel formation.²³ In an early-phase clinical trial, belzutifan was well tolerated and showed preliminary anti-tumor activity in patients who had already been through multiple prior treatments.²⁴ It has since been approved for VHL disease-associated tumors and is being studied in broader ccRCC populations. The development of HIF-2α inhibitors represents a shift from attacking the downstream consequences of VHL loss (like excess VEGF) toward targeting the root cause more directly.

Why Tumors Stop Responding to Treatment

A frustrating reality of ccRCC treatment is that most tumors eventually develop resistance to VEGF-targeting drugs. The mechanisms are varied. Tumors can switch on alternative pathways to build blood vessels, bypassing the blocked VEGF pathway. They can also undergo changes that make them more invasive, pump drugs out of cells more efficiently, or reshape the surrounding tissue environment to support continued growth.²⁵ Some of this resistance is acquired gradually during treatment, driven by an “angiogenic switch” that ramps up alternative blood-vessel-forming signals as VEGF is suppressed.²⁶ Understanding these mechanisms is a major area of active research, because overcoming resistance could extend survival meaningfully.

The Immune Microenvironment

ccRCC occupies an interesting position among cancers in terms of immune biology. Compared to many other tumor types, ccRCC tends to be heavily infiltrated by immune cells, including T cells. Studies ranking cancers by immune infiltration have consistently placed ccRCC among the highest.²⁷ That high level of immune infiltration is part of why checkpoint inhibitors work as well as they do in this disease. But the picture is more nuanced than “more immune cells equals better outcomes.” The same research identified three distinct immune profiles among ccRCC tumors: T cell-enriched, heterogeneously infiltrated, and non-infiltrated. Interestingly, the level of immune activity in these tumors does not appear to be driven by mutation load the way it is in some other cancers. Instead, it correlates with how well the tumor cells display their internal contents to the immune system through a process involving antigen-presenting machinery.

Emerging Diagnostic Tools

Traditional diagnosis of ccRCC relies on imaging (usually CT or MRI) followed by surgical removal and microscopic examination. Two areas of technology are beginning to change that picture.

Liquid biopsies, which analyze fragments of tumor DNA or intact tumor cells circulating in the blood, offer a way to characterize a tumor without a needle or scalpel. For ccRCC specifically, detecting circulating tumor DNA and circulating tumor cells has shown promise for cancer detection, monitoring treatment response, and tracking disease progression over time.²⁸ The technology is not yet routine in clinical practice, but the pace of development suggests it could become a standard part of ccRCC management in coming years.

Artificial intelligence applied to standard CT scans is another frontier. Researchers have built AI models that can predict tumor grade and molecular features from imaging alone. One multicenter study developed a model that predicted pathological grade with an area under the curve of 0.82 to 0.84 across different validation sets.²⁹ Another used CT-based radiomics to predict BAP1 mutation status with about 83 percent accuracy, which matters because BAP1 status has real implications for prognosis.³⁰ Features from the tissue immediately surrounding the tumor, not just the tumor itself, also carry predictive information about grade.³¹ The practical appeal here is clear: if a CT scan you are already getting can tell your doctor something about your tumor’s genetics and aggressiveness before any tissue is removed, that could reshape early treatment decisions.

Sarcomatoid Transformation

A small percentage of ccRCC tumors undergo what is called sarcomatoid transformation, where the cancer cells take on a more spindle-shaped, aggressive appearance. This change is associated with worse prognosis and has sometimes been attributed to a process called epithelial-mesenchymal transition, where cells lose their typical organized structure and become more mobile and invasive. However, recent molecular analysis suggests the reality is more subtle than a full transformation. Comparing the molecular markers in sarcomatoid regions versus standard ccRCC regions, researchers found discrete differences between the two rather than a clean switch from one cell state to another, suggesting these tumors may occupy intermediate states rather than fully converting.³² This matters therapeutically because tumors stuck in a partial transition may respond differently to treatment than those that have fully transformed, and understanding where a given tumor sits on that spectrum could eventually guide drug selection.